This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Winners & Losers: Take-Two

Standard & Poor's said it would maintain its triple-A ratings on bond insurers Ambac (ABK) and MBIA (MBI - Get Report).

Shares of Ambac were jumping 15.1% to $12.33, and MBIA was up 22.3% to $14.89.

Shares of video-games company Take-Two (TTWO - Get Report) soared $9.53, or 54.9%, to $26.89 after its larger rival Electronic Arts (ERTS) made a $2-billion, or $26-a-share, unsolicited offer.

After Take-Two's management rejected the bid , EA turned hostile, taking its offer to Take-Two's shareholders. EA's stock fell $2.60, or 5.2%, to $47.14.

Shares of Genentech's (DNA) were climbing 8% after the FDA late Friday approved the use of Avastin in breast cancer. The accelerated approval was based on the benefits to progression-free survival -- the delayed growth of tumors -- when the drug is added to chemotherapy.

Avastin, currently a treatment for colorectal and non-small-cell lung cancers, is expected to receive full approval in breast cancer when the company submits data from two more studies. The approval came as something of a surprise, since an FDA panel voted 5-4 in December to recommend against the breast cancer approval.

Genentech shares were adding $6 to $77.60.

Heading in the opposite direction, small-cap Immtech Pharmaceuticals (IMM) plunged 45% after the company said it would discontinue the development program for pafuramidine, a late-stage investigational therapy for a type of pneumonia in AIDS patients. The action is in response to instances of abnormal kidney function, which resulted in hospitalization of several study participants.

Following the discontinuation of the study, Immtech won't receive further payments from Strativa, a division of Par Pharmaceuticals (PRX) that has commercialization rights to the drug candidate. Immtech shares tanked 90 cents to $1.10.

On the losing side was FirstFed Financial (FED), which fell 4% to $32.80 after the company increased its total nonperforming assets.

Meanwhile, Houston's Tesco (TESO - Get Report), which creates technology solutions for the upstream energy industry, jumped 13.3% to $23.45 on fourth-quarter earnings. The company posted income of $6.6 million, or 18 cents a share, vs. $10.5 million, or 29 cents a share, in 2006. This year's fourth-quarter earnings include a $1.2 million loss related to expiration of its Turnkey E&P warrants. Analysts polled by Thomson Financial were looking for EPS of 17 cents, excluding items.

Shares of Marvell Technology (MRVL - Get Report) gained 65 cents, or 5.9%, to $11.77 after a report in Barron's said the company could see its shares double in two years as its chips get integrated into new products.

Shares of ethanol company Verenium (VRNM) got pounded down 12.5% to $3.08 after the Cambridge, Mass., firm announced a $54 million convertible debt offering. Verenium is issuing senior convertible notes maturing April 1, 2012, and exchanging $16.7 million of these notes for $18.5 million of existing 5.5% convertible senior notes. The company said it was raising the money for general working capital purposes.
This article was written by a staff member of TheStreet.com.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
MBI $5.95 0.00%
MRVL $12.44 0.00%
TESO $9.60 0.00%
TTWO $31.58 0.00%
AAPL $121.30 0.00%

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs